Sitc 2024 Ak132. Ak132 is a bispecific antibody developed by akeso, targeting the recombinant humanized claudin18.2 (cldn18.2) splice variant 2 and cd47 for the treatment of various. Ak132 is an asymmetric bispecific antibody with a 1+1 valency, designed to simultaneously target and block cldn18.2 and cd47.

Akeso published mechanism of action for cldn18.2/cd47 bispecific antibody ak132 for the first time at sitc annual meeting pr newswire hong kong, nov. Ak132 efficiently binds to cldn18.2 and cd47, exerting antitumor effects through multiple mechanisms;